

19 Apr 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/04/19/3276675/0/en/monopar-presents-phase-3-data-showing-greater-neurologic-benefit-with-alxn1840-vs-soc-in-wilson-disease-patients-with-neurologic-symptoms-at-aan-2026.html